10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis

Evidence-Based Treatment Pathways for PPD

Postpartum Depression Management Pathway
├── Mild to Moderate PPD (EPDS 10 - 14)
│   ├── First-Line: Evidence-Based Psychotherapy
│   │   ├── Cognitive Behavioral Therapy (CBT - cognitive restructuring)
│   │   └── Interpersonal Psychotherapy (IPT - role transitions & support)
│   └── Non-Pharmacologic: Peer support groups, protected sleep, structured aerobic exercise
└── Moderate to Severe PPD (EPDS ≥15 or Refractory)
    ├── Combined Treatment: Psychotherapy PLUS Pharmacotherapy
    ├── Selective Serotonin Reuptake Inhibitors (SSRIs)
    │   ├── Sertraline (Zoloft) 25 - 50 mg PO daily, titrate to 100 - 200 mg (PREFERRED)
    │   └── Escitalopram (Lexapro) or Paroxetine (Paxil) (Alternatives)
    └── Neuroactive Steroids (Severe Acute PPD)
        └── Zuranolone (Zurzuvae) 50 mg PO daily in evening with fat meal x 14 days

1. Evidence-Based Psychotherapy

• Cognitive Behavioral Therapy (CBT): The most extensively validated psychological treatment for perinatal depression. Targets and restructures negative cognitive distortions, automatic catastrophizing thoughts, and maladaptive perfectionism regarding motherhood.
• Interpersonal Psychotherapy (IPT): Focuses on maternal role transitions, resolving marital/interpersonal conflict, and expanding social support networks.

2. Selective Serotonin Reuptake Inhibitors (SSRIs) & Lactation Safety

Pharmacotherapy is indicated for moderate-to-severe PPD, marked functional impairment, suicidal ideation, or when psychotherapy alone is inadequate.

• Sertraline (Zoloft) — The Gold Standard:
  • The preferred first-line SSRI in breastfeeding women.
  • Pharmacokinetics: High plasma protein binding (98%) and extensive hepatic clearance result in minimal excretion into human breast milk. The Relative Infant Dose (RID) is consistently <2% (well below the accepted 10% safety threshold), and infant serum concentrations are undetectable in over 90% of tested infants.
  • Dosing: Initiate at 25 to 50 mg PO daily in the morning with food; titrate in 25–50 mg increments every 1 to 2 weeks up to an effective therapeutic dose of 100 to 200 mg daily. Full therapeutic antidepressant response typically requires 4 to 6 weeks.
• Alternative SSRIs:
  • Paroxetine (Paxil): Also has very low breast milk transmission (RID 1% to 2%), but carries higher sedation and anticholinergic side effects; associated with challenging discontinuation syndromes.
  • Escitalopram (Lexapro) & Citalopram (Celexa): Low to moderate milk excretion (RID 3% to 7%); excellent options if the patient had prior successful response.
  • Fluoxetine (Prozac): Has a very long elimination half-life and an active metabolite (norfluoxetine) that accumulates in breast milk (RID 5% to 9%). Can cause transient infant irritability, colic, or loose stools. If a mother was stabilized on fluoxetine during pregnancy, she may continue it; however, it is generally not initiated de novo during lactation.
• Infant Monitoring: Counsel lactating mothers on SSRIs to monitor the infant for feeding difficulties, excessive somnolence, irritability, or poor weight gain.

3. Neuroactive Steroid Therapeutics (GABA Modulators)

• Zuranolone (Zurzuvae): First FDA-approved oral neuroactive steroid for the treatment of postpartum depression in adults.
  • Mechanism: Positive allosteric modulator of $\text{GABA}_\text{A}$ receptors, rapidly restoring neural inhibition disrupted by allopregnanolone withdrawal.
  • Dosing: 50 mg orally once daily in the evening taken with a meal containing fat for a completed 14-day course.
  • Clinical Advantage: Rapid onset of significant antidepressant action observed as early as Day 3, maintaining efficacy after treatment completion.
  • Adverse Effects & Safety: CNS depression (somnolence, dizziness, sedation). Patients must be instructed not to drive or operate machinery for at least 12 hours following each evening dose. Human lactation data is limited; clinicians should engage in shared decision-making regarding temporary pumping and discarding during the active 14-day window if maximal caution is desired.
• Brexanolone (Zulresso): Continuous 60-hour intravenous infusion of allopregnanolone requiring inpatient admission and continuous pulse oximetry monitoring for excessive sedation and loss of consciousness.

---

Postpartum Anxiety & Obsessive-Compulsive Disorder (OCD)

Postpartum Generalized Anxiety & Panic

Postpartum anxiety affects up to 10% to 15% of women, characterized by persistent, excessive worries regarding infant health, autonomic hyperarousal, shortness of breath, trembling, and panic attacks.

Postpartum OCD & Intrusive Thoughts

Between 70% and 90% of all postpartum women experience occasional intrusive thoughts regarding harm befalling their baby. In postpartum OCD, these thoughts become pervasive, distressing, and debilitating.

The Critical Clinical Distinction: Egodystonic vs. Egosyntonic Thoughts

The certified nurse-midwife must master the distinction between obsessive intrusive thoughts and psychotic delusions. Misidentifying intrusive thoughts as psychosis results in traumatic, unnecessary psychiatric hospitalizations and inappropriate child separation.

---

Postpartum Psychosis: The Ultimate Psychiatric Emergency

Postpartum psychosis (puerperal psychosis) is a severe, rapidly decompensating psychiatric emergency that demands immediate clinical action.

Epidemiology & Chronology

• Incidence: Occurs in 1 to 2 per 1,000 live births (0.1% to 0.2%).
• Onset: Characteristically acute and abrupt, presenting within the first 2 to 4 weeks postpartum, with most cases emerging between postpartum days 3 and 14.
• Primary Risk Factor: Prior personal history of Bipolar I Disorder carries an astonishing 25% to 50% risk of postpartum psychosis. A prior history of postpartum psychosis carries an equivalent recurrence risk in subsequent pregnancies. Family history of bipolar disorder is also a major predisposing factor.

Clinical Presentation

• Early Prodrome: Severe, intractable insomnia with complete absence of fatigue, restlessness, mood lability, and marked cognitive confusion.
• Full Psychotic Syndrome:
  • Cognitive Delirium: Waxing and waning sensorium, disorientation to time and place, memory deficits, and extreme perplexity.
  • Bizarre Delusions: Egosyntonic, fixed false beliefs focused on the baby (e.g., the infant is demonic, possessed, deformed, or must be sacrificed for spiritual cleansing).
  • Hallucinations: Auditory command hallucinations instructing the mother to harm herself or kill the infant; visual or olfactory hallucinations.
  • Manic / Mixed States: Rapid, pressured speech, flight of ideas, psychomotor agitation, disorganized behavior, and extreme paranoia.
• Mortality Risk: If untreated, postpartum psychosis carries a 4% rate of infanticide and a 5% rate of maternal suicide.

Emergency Midwifery Management Protocol

When postpartum psychosis is suspected, the CNM must execute an immediate, non-negotiable safety and crisis protocol:

1. ENSURE IMMEDIATE INFANT SAFETY:
   • The mother must NEVER be left unattended or alone with the infant under any circumstances.
   • Immediately place the infant in the custody of a safe, trusted partner, family member, or hospital nursery staff.
2. Immediate Emergency Psychiatric Evaluation:
   • Do not schedule an outpatient referral. Escort the patient directly to the nearest Emergency Department or psychiatric crisis evaluation center.
3. Inpatient Psychiatric Hospitalization:
   • Secure immediate admission to a locked inpatient psychiatric unit (ideally a specialized perinatal Mother-Baby Psychiatric Unit if available).
4. Pharmacotherapy:
   • Initiate second-generation atypical antipsychotics (olanzapine, quetiapine, risperidone), mood stabilizers (lithium, divalproex sodium), and short-term benzodiazepines for acute behavioral agitation.
   • Electroconvulsive Therapy (ECT): Recognized as a rapid, exceptionally safe, and highly effective treatment of choice for severe or medication-refractory postpartum psychosis, particularly in the presence of catatonia, severe mania, or acute suicidal/infanticidal delirium.